The publication output related to lung cancer and heart failure showed a significant annual growth rate of 7.92% from 2014 to 2024, reflecting increasing research interest in treatment-induced cardiotoxicity.
Bibliometric analysis reveals a rapidly growing research focus on the intersection of lung cancer and heart failure, driven largely by the cardiotoxic effects of modern cancer therapies like immune checkpoint inhibitors.
This innovative mapping research highlights an increasing focus on the link between LC and HF, particularly concerning treatment-induced cardiotoxicity. Nonetheless, studies on their two-way interaction are still scarce, pointing to a promising yet under-researched area. Combining oncology and cardiology could reveal new insights to tailor personalized care and enhance results. Our research provides a foundation for future interdisciplinary investigations in the developing field of cardio-oncology.
Lin et al. (Fri,) conducted a other in lung cancer and heart failure (n=531). The publication output related to lung cancer and heart failure showed a significant annual growth rate of 7.92% from 2014 to 2024, reflecting increasing research interest in treatment-induced cardiotoxicity.